KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer Last updated on Nov 9, 2024 Photo by Oleg Laptev / Unsplash Previous CALLA: Durvalumab versus placebo with chemoradiotherapy Next Publications Update # 51
Photo by Oleg Laptev / Unsplash
